Abstract：Objective To investigate changes in complement component 3 (C3) levels in children with sepsis and its correlation with the severity of sepsis and to explore the significance of C3 in predicting mortality in children with sepsis. Methods A retrospective analysis was conducted on 529 children with sepsis who were admitted to the Pediatric Intensive Care Unit in Hunan Children's Hospital between November 2019 and September 2021. The children were categorized into two groups based on their prognosis at day 28 after sepsis diagnosis: the survival group (n=471) and the death group (n=58). Additionally, the children were divided into normal C3 group (n=273) and reduced C3 group (n=256) based on the median C3 level (0.77 g/L) within 24 hours of admission. Clinical data and laboratory markers were compared between the groups, and assess the predictive value of C3 levels in relation to sepsis-related mortality. Results The death group exhibited significantly lower C3 levels compared to the survival group (P<0.05). Multivariate logistic regression analysis revealed that higher pediatric Sequential Organ Failure Assessment (p-SOFA) scores and lower C3 levels were closely associated with sepsis-related mortality (P<0.05). The receiver operating characteristic curve (ROC) analysis demonstrated that combination of p-SOFA scores and C3 levels yielded an area under the ROC curve of 0.852, which was higher than that of each indicator alone (P<0.05). Conclusions C3 can serve as an indicator to assess the severity and prognosis of sepsis in children. The combination of p-SOFA scores and C3 levels holds good predictive value for mortality in children with sepsis.
PENG Zhi-Hui,YAN Hai-Peng,LU Xiu-Lan et al. Value of complement component 3 in predicting the prognosis of children with sepsis[J]. CJCP, 2023, 25(9): 941-946.
Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study[J]. Am J Respir Crit Care Med, 2015, 191(10): 1147-1157. PMID: 25734408. PMCID: PMC4451622. DOI: 10.1164/rccm.201412-2323OC.
Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation[J]. Nat Rev Nephrol, 2012, 8(11): 622-633. PMID: 22986360. DOI: 10.1038/nrneph.2012.195.
Abe T, Kubo K, Izumoto S, et al. Complement activation in human sepsis is related to sepsis-induced disseminated intravascular coagulation[J]. Shock, 2020, 54(2): 198-204. PMID: 31917735. DOI: 10.1097/SHK.0000000000001504.
Zhao X, Chen YX, Li CS. Predictive value of the complement system for sepsis-induced disseminated intravascular coagulation in septic patients in emergency department[J]. J Crit Care, 2015, 30(2): 290-295. PMID: 25547047. DOI: 10.1016/j.jcrc.2014.11.007.
Mannes M, Mastellos DC, Ekdahl KN, et al. Complement C3 activation in the ICU: disease and therapy as Bonnie and Clyde[J]. Semin Immunol, 2022, 60: 101640. PMID: 35853795. DOI: 10.1016/j.smim.2022.101640.
